The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

FDA balances costs, patient safety in the biologics and personalized medicine revolution

| July 23, 2012

Sometimes what you see is not all you get. Whether or not you support healthcare reform, the implementation of any vast, complex legislation can result in unintended consequences. That’s certainly the case when it comes to the emerging era of biologics—a new class of treatments made from living organisms. Most therapeutic drugs are made up of simple molecules mixed together. In contrast, “biologic drugs” are made from far more complex human or animal proteins. Rather than treating the disease’s consequences, biologics work by blocking diseases early in their development, in the immune system, and can be individually tailored to a the person taking the medicine—a revolutionary turn along the windy road toward our personalized medicine future.

View the original article here: FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine … – Forbes

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend